---
title: In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline
  treatment for amyotrophic lateral sclerosis
date: '2024-01-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38240416/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240119170735&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: These results underline the need to consider individual
  disease progression at baseline in future ALS studies. Very slow disease progressors
  compromise the statistical power of studies with treatment durations of 12-18 months
  using clinical endpoints. Analysis of MAOB and DRD2 SNPs revealed no clear relationship
  to any outcome parameter. More insights are expected from future studies elucidating
  whether patients with DRD2(CC) genotype (Rs2283265) show a pronounced benefit ...'
disable_comments: true
---
CONCLUSIONS: These results underline the need to consider individual disease progression at baseline in future ALS studies. Very slow disease progressors compromise the statistical power of studies with treatment durations of 12-18 months using clinical endpoints. Analysis of MAOB and DRD2 SNPs revealed no clear relationship to any outcome parameter. More insights are expected from future studies elucidating whether patients with DRD2(CC) genotype (Rs2283265) show a pronounced benefit ...